Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease.
Saved in:
| Title: | Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease. |
|---|---|
| Authors: | Radcliffe NM; Mt Sinai School of Medicine, New York, NY, USA., Sheppard J; Virginia Eye Consultants, Norfolk, VA, USA., Simmons B; Vision Institute, Colorado Springs, CO, USA., Owen D; AbbVie Inc., North Chicago, IL, USA., Nguyen A; AbbVie Inc., North Chicago, IL, USA., Cavanagh B; Aldeyra Therapeutics, Inc, 131 Hartwell Avenue, Suite 320, Lexington, MA, 02421, USA., Brady TC; Aldeyra Therapeutics, Inc, 131 Hartwell Avenue, Suite 320, Lexington, MA, 02421, USA. tbrady@aldeyra.com. |
| Source: | Ophthalmology and therapy [Ophthalmol Ther] 2026 May; Vol. 15 (5), pp. 1807-1821. Date of Electronic Publication: 2026 Apr 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Country of Publication: England NLM ID: 101634502 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8245 (Print) NLM ISO Abbreviation: Ophthalmol Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
